(dtpa-phe(1))-octreotide and Somatostatinoma

(dtpa-phe(1))-octreotide has been researched along with Somatostatinoma* in 2 studies

Other Studies

2 other study(ies) available for (dtpa-phe(1))-octreotide and Somatostatinoma

Article	Year
Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut, 1998, Volume: 42, Issue:6 Somatostatin receptor scintigraphy (SRS) and octreotide therapy have both changed the management of gastroenteropancreatic endocrine tumours, but very few data are available on the use of SRS and octreotide to visualise and treat somatostatinomas.. The results of SRS and octreotide treatment in three somatostatinoma patients were examined.. SRS was able to detect extensive hepatic involvement in patient 1, one hepatic and one pancreatic lesion in patient 2, and one hepatic lesion in patient 3. Octreotide therapy (0.5 mg/day subcutaneously) was effective in decreasing plasma levels of somatostatin in all three patients. Symptoms (diabetes and diarrhoea) were greatly improved in the two patients with "somatostatinoma syndrome".. The study shows that somatostatinoma, like most other gastroenteropancreatic endocrine tumours, possesses functioning somatostatin receptors. Topics: Aged; Antineoplastic Agents, Hormonal; Female; Humans; Liver Neoplasms; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Somatostatinoma	1998
Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1997, Volume: 38, Issue:6 This article describes the visualization of a pancreatic somatostatinoma and liver metastases using 111In-pentetreotide imaging in a patient with somatostatinoma syndrome. A 61-yr-old woman with gallbladder stones, diabetes, weight loss, diarrhea and steatorrhea, immunohistochemical diagnosis of somatostatinoma (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy. Six sites of focal abnormal 111In-pentetreotide hyperfixation were found: three in the liver and three in the pancreatic area. This case report demonstrates that in vivo detection of somatostatinoma with somatostatin receptor imaging is possible in the presence of high levels of circulating somatostatin, suggesting that receptor downregulation has not occurred. Topics: Female; Humans; Indium Radioisotopes; Liver Neoplasms; Middle Aged; Octreotide; Pancreatic Neoplasms; Pentetic Acid; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatinoma; Tomography, Emission-Computed, Single-Photon	1997

Article

Year

Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours.

Gut, 1998, Volume: 42, Issue:6

Somatostatin receptor scintigraphy (SRS) and octreotide therapy have both changed the management of gastroenteropancreatic endocrine tumours, but very few data are available on the use of SRS and octreotide to visualise and treat somatostatinomas.. The results of SRS and octreotide treatment in three somatostatinoma patients were examined.. SRS was able to detect extensive hepatic involvement in patient 1, one hepatic and one pancreatic lesion in patient 2, and one hepatic lesion in patient 3. Octreotide therapy (0.5 mg/day subcutaneously) was effective in decreasing plasma levels of somatostatin in all three patients. Symptoms (diabetes and diarrhoea) were greatly improved in the two patients with "somatostatinoma syndrome".. The study shows that somatostatinoma, like most other gastroenteropancreatic endocrine tumours, possesses functioning somatostatin receptors.

Topics: Aged; Antineoplastic Agents, Hormonal; Female; Humans; Liver Neoplasms; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Somatostatinoma

1998

Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1997, Volume: 38, Issue:6

This article describes the visualization of a pancreatic somatostatinoma and liver metastases using 111In-pentetreotide imaging in a patient with somatostatinoma syndrome. A 61-yr-old woman with gallbladder stones, diabetes, weight loss, diarrhea and steatorrhea, immunohistochemical diagnosis of somatostatinoma (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy. Six sites of focal abnormal 111In-pentetreotide hyperfixation were found: three in the liver and three in the pancreatic area. This case report demonstrates that in vivo detection of somatostatinoma with somatostatin receptor imaging is possible in the presence of high levels of circulating somatostatin, suggesting that receptor downregulation has not occurred.

Topics: Female; Humans; Indium Radioisotopes; Liver Neoplasms; Middle Aged; Octreotide; Pancreatic Neoplasms; Pentetic Acid; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatinoma; Tomography, Emission-Computed, Single-Photon

1997